Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Molten Ventures
Deal Size : $14.6 million
Deal Type : Series A Financing
IMU Biosciences Secures £11.5 Million Series A to Advance Immune Precision Medicine
Details : The proceeds will support IMU's CytAtlas™ platform to revolutionize immune-powered precision medicine and accelerate drug development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Molten Ventures
Deal Size : $14.6 million
Deal Type : Series A Financing